Long COVID and Related Infection-Associated Chronic Illnesses (F2)
October 11-14, 2027
| Fairmont Hotel Vancouver, Vancouver, BC, Canada
Michael J Peluso, Carmen Scheibenbogen, E. John Wherry and Letícia Soares
| 4:00–8:00 PM |
Registration |
|
| 6:00–8:00 PM |
Welcome Mixer |
|
Tuesday, October 12, 2027
| 8:00–9:00 AM |
Keynote Address |
|
| |
Eric Topol †, The Scripps Research Institute
Pathogens as a Cause of Chronic Illness and the Implications for Human Health |
|
| 9:00–11:15 AM |
Immune Dysregulation, Autoimmunity, and Host Susceptibility |
|
| |
Carmen Scheibenbogen, Charite University
Autoimmunity as a Driver of ME/CFS |
|
| |
Nadia R Roan †, University of California, San Francisco
Immunobiology of Sex Differences in Long COVID |
|
| |
Jessica Lasky-Su †, Harvard Medical School
What RECOVER-Omics Is Teaching Us About Long COVID |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:30–9:50 AM |
Coffee Break |
|
| 11:25–12:25 PM |
Panel Discussion 1: Clinical Heterogeneity Across Populations and Conditions |
|
| 12:25–1:00 PM |
Poster Setup |
|
| 12:25–2:30 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 2:30–4:30 PM |
Symposia Spotlight 1: Emerging Findings from Clinical Trials |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Tissue and Neuroimmune Biology of Infection-Associated Chronic Illness |
|
| |
Akiko Iwasaki †, Yale University/HHMI
The Neuroimmune Axis in Infection-Associated Chronic Illness |
|
| |
Marcus Buggert †, Karolinska Institutet
Tissue-Based Immunologic Endotyping in Long COVID |
|
| |
Michelle James †, Stanford University
Imaging the Biology of Long COVID and ME/CFS |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Wednesday, October 13, 2027
| 8:00–11:00 AM |
Persistent and Reactivated Pathogens Across Chronic Disease |
|
| |
James Stone †, Massachusetts General Hospital
Mapping SARS-CoV-2 Persistence Through the RECOVER Autopsy Program |
|
| |
Christian Münz †, University of Zurich
EBV Immune Control in Infection-Associated Chronic Disease |
|
| |
Allen Eghrari †, Johns Hopkins School of Medicine Faculty
Pathogen Persistence and Immune Dysfunction Following Ebola Virus Disease |
|
| |
Monica Embers †, Tulane University
Borrelia Persistence in Lyme Disease |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:00–1:00 PM |
Poster Setup |
|
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
|
| 3:00–4:30 PM |
Career Roundtable |
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–7:00 PM |
Diverse and Emerging Mechanisms of Infection-Associated Chronic Illness |
|
| |
Rob Wust †, Vrije University Amsterdam
Skeletal Muscle Dysfunction and Post-Exertional Malaise in Long COVID |
|
| |
Lael Yonker †, UT Southwestern Medical Center
Gut Barrier Dysfunction, Viral Antigen, and Microbial Translocation in Adults and Children with Long COVID |
|
| |
E. John Wherry, University of Pennsylvania
Immune Signatures of Persistent Microbes |
|
| |
Katerina Akassoglou †, Icahn School of Medicine at Mount Sinai
Spike-Fibrin Interactions in Thromboinflammation and Neuropathology After COVID-19 |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
Thursday, October 14, 2027
| 12:10–5:00 PM |
On Own for Lunch |
|
| 8:00–11:00 AM |
Challenges and Opportunities in Infection-Associated Chronic Illness Research |
|
| |
Michael J Peluso, University of California, San Francisco
The Challenge of Biomarker Development in Long COVID and Lessons from the UCSF VIPER Program |
|
| |
Leonard H Calabrese †, Cleveland Clinic
The Neurobiology of Placebo and Nocebo Effects in Chronic Illness |
|
| |
Letícia Soares, Patient-Led Research Collaborative
What Patients Say We Should Measure in Long COVID Clinical Trials |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 9:00–9:20 AM |
Coffee Break |
|
| 11:10–12:10 PM |
Panel Discussion 2: Building a Diagnostic and Therapeutic Development Ecosystem |
|
| 2:30–4:30 PM |
Symposia Spotlight 2: New Tools for Diagnosis, Stratification, and Mechanistic Discovery |
|
| |
Short Talks Chosen from Abstracts
|
|
| 4:30–5:00 PM |
Coffee Available |
|
| 5:00–6:45 PM |
What Clinical Trials Can Teach Us About Disease Biology |
|
| |
Peter Marks †, Eli Lilly
Developing Drugs for a Disease Without Clear Diagnostic Markers |
|
| |
Birgit Sawitzki †, Berlin Institute of Health at Charité
What NKSG Trials Reveal About Long COVID and ME/CFS Biology |
|
| |
Øystein Fluge †, Haukeland University Hospital / University of Bergen
Targeting B Cells and Plasma Cells to Probe ME/CFS Pathogenesis |
|
| |
Short Talk(s) Chosen from Abstracts
|
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions |
|
| 7:00–8:00 PM |
Social Hour with Dinner |
|
| 8:00–11:00 PM |
Entertainment |
|
